Novo Nordisk Shares Plunge 21% Toward Worst Day In 40 Years—As Ozempic Sales Expected To Slow
1. Novo Nordisk shares fell over 21%, largest drop since the 1980s. 2. Full-year sales guidance for 2025 reduced to 8%-14%. 3. Growth slowdown expected due to competition and compounded alternatives. 4. Novo Nordisk warns about safety risks from compounded drugs. 5. New CEO Maziar Mike Doustdar appointed, succeeding Lars Fruergaard Jorgensen.